ArticleMolecular pharmaceutics2014
Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer.
Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 111 citations in OpenAlex.
- Mechanisms and therapeutic design of stimuli-responsive vesicular nanocarriers for melanoma.International journal of pharmaceutics: X · 2026Review
- Peptomer Linkers Enable Kinetic Control over Co-Delivery of Multiple Chemotherapeutics.Advanced healthcare materials · 2026Article
- Hepatotropic Nanomedicine and Targeted Nanocarriers for Liver Diseases and Hepatocellular Carcinoma.International journal of nanomedicine · 2026Review
- Silver integrated hybrids and nanocomposites for next-generation biomedicine: Beyond antimicrobial coatings toward smart sense-response-heal platforms.Materials today. Bio · 2025Review
- Fibrotic Fortresses and Therapeutic Frontiers: Pancreatic Stellate Cells and the Extracellular Matrix in Pancreatic Cancer.Cancer medicine · 2025Review
- Dual-enzyme activated theranostic nanoparticles for image-guided glioblastoma therapy.Scientific reports · 2025Article
- Applications of Matrix Metalloproteinase-9-Related Nanomedicines in Tumors and Vascular Diseases.Pharmaceutics · 2025Review
- Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment.Pharmaceutics · 2025Review
- Intertumoral and intratumoral barriers as approaches for drug delivery and theranostics to solid tumors using stimuli-responsive materials.Mikrochimica acta · 2024Review
- Drug Delivery Strategies for the Treatment of Pancreatic Cancer.Pharmaceutics · 2023Review
- Passing of Nanocarriers across the Histohematic Barriers: Current Approaches for Tumor Theranostics.Nanomaterials (Basel, Switzerland) · 2023Review
- Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment.Cancers · 2023Review
- Encapsulation of Gold-Based Anticancer Agents in Protease-Degradable Peptide Nanofilaments Enhances Their Potency.Journal of the American Chemical Society · 2023Article
- Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications.Pharmaceutics · 2022Review
- Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.Journal of hematology & oncology · 2022Review
- The Impact of Tyrosine Iodination on the Aggregation and Cleavage Kinetics of MMP-9-Responsive Peptide Sequences.ACS biomaterials science & engineering · 2022Article
- Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy.Frontiers in bioengineering and biotechnology · 2022Review
- The Effective Combination between 3D Cancer Models and Stimuli-Responsive Nanoscale Drug Delivery Systems.Cells · 2021Review
- Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy.Journal of nanobiotechnology · 2021Review
- CHARMM-GUI Membrane Builder for Lipid Nanoparticles with Ionizable Cationic Lipids and PEGylated Lipids.Journal of chemical information and modeling · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Significant differences in biochemical parameters between normal and tumor tissues offer an opportunity to chemically design drug carriers which respond to these changes and deliver the drugs at the desired site. For example, overexpression of the matrix metalloproteinase-9 (MMP-9) enzyme in the extracellular matrix of tumor tissues can act as a trigger to chemically modulate the drug delivery from the carriers. In this study, we have synthesized an MMP-9-cleavable, collagen mimetic lipopeptide which forms nanosized vesicles with the POPC, POPE-SS-PEG, and cholesteryl-hemisuccinate lipids. The lipopeptide retains the triple-helical conformation when incorporated into these nanovesicles. The PEG groups shield the substrate lipopeptides from hydrolysis by MMP-9. However, in the presence of elevated glutathione levels, the PEG groups are reductively removed, exposing the lipopeptides to MMP-9. The resultant peptide-bond cleavage disturbs the vesicles' lipid bilayer, leading to the release of encapsulated contents. These PEGylated nanovesicles are capable of encapsulating the anticancer drug gemcitabine with 50% efficiency. They were stable in physiological conditions and in human serum. Effective drug release was demonstrated using the pancreatic ductal carcinoma cells (PANC-1 and MIAPaCa-2) in two-dimensional and three-dimensional "tumor-like" spheroid cultures. A reduction in tumor growth was observed after intravenous administration of the gemcitabine-encapsulated nanovesicles in the xenograft model of athymic, female nude mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.